Edwards and colleagues provide a timely account of the regulatory challenges facing new approach methodologies (NAMs) within the European medicines regulatory framework, rightly identifying fragmented terminology, unclear contexts of use and insufficient collaborative learning as key barriers (Nat. Rev. Drug Discov. 24, 571–572; 2025)1.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Nicolas
Contact Nicolas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack